Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program

Cited by (351)

Items 201–300 of 351

1. Atrial Fibrillation and the Renin-Angiotensin-Aldosterone System
   Stefano Perlini, Fabio Belluzzi, Francesco Salinaro, Francesco Musc · 2013 · InTech eBooks
2. Prognosis of the life of patients with chronic heart failure and atrial fibrilla-tion, depending on the control of hemodynamic parameters and tolerance to physical exertion in the background of basic therapy
   Виноградова Надежда Георгиевна, Поляков Дмитрий Сергеевич, Igor V. Fomin, М. М. Жиркова · 2019 · Kardiologiia
3. Atrial fibrillation and arterial hypertension
   Е. И. Баранова · 2011 · Arterial’naya Gipertenziya (Arterial Hypertension)
4. Smokeless tobacco country: from nicotine dependency to oral problems and cancer.
   Arden G. Christen, James L. McDonald · 1987 · PubMed
5. Eurasian Association of Cardiology (EAC)/ National Society of Heart Failure And Myocardial Disease (NSHFMD) guidelines for the diagnosis and treatment of chronic heart failure (2024)
   Sergey N. Tereshchenko, И. В. Жиров, Tatiana M. Uskach, Marina A. Saidova, Golitsyn Sp, E. M. Rimskaya, Насонова Светлана Николаевна, O. Yu. Narusov, Alfiya A. Safiullina, Andrew S. Tereshchenko et al. · 2024 · Eurasian heart journal
6. Non-Anticoagulation Strategies Aimed at Primary Stroke Prevention in Nascent Atrial Fibrillation
   Luca Sgarra, Vanessa Desantis, Andrea Matteucci, Vincenzo Paolo Caccavo, Federica Troisi, Antonio Di Monaco, Francesco Mangini, Grigorios Katsouras, Andrea Igoren Guaricci, Michele Luca Dadamo et al. · 2025 · Biomedicines
7. European Journal of Heart Failure Consensus Statement. Heart Failure Pharmacotherapy for Patients with Heart Failure with Reduced Ejection Fraction and Concomitant Atrial Fibrillation: Review of Evidence and Call to Action
   Mark Luedde, Stefan Agewall, Giuseppe Ambrosio, Antoni Bayés‐Genís, Claudio Borghi, Elisabetta Cerbai, Gheorghe Andrei Dan, Heinz Drexel, Péter Ferdinándy, Erik Lerkevang Grove et al. · 2025 · European Journal of Heart Failure
8. Adjuvant Therapy for Atrial Fibrillation
   Khaja Mohammed, Peter Russell Kowey, Simone Musco · 2009 · Future Cardiology
9. Regenerative therapies in electrophysiology and pacing
   Michael R. Rosen, Peter R. Brink, Ira S. Cohen, Peter Danilo, Richard B. Robinson, Amy B. Rosen, Matthias J. Szabolcs · 2008 · Journal of Interventional Cardiac Electrophysiology
10. Candesartan cilexetil: an update
    Alexander Joost, Heribert Schunkert, Peter Walter Radke · 2011 · Expert Opinion on Pharmacotherapy
11. Upstream Therapy for Atrial Fibrillation in Heart Failure
    Andreas Goette · 2013 · Heart Failure Clinics
12. The Year in Heart Failure
    W.H. Wilson Tang, Gary S. Francis · 2006 · Journal of the American College of Cardiology
13. Candesartan: widening indications for this angiotensin II receptor blocker?
    Buddhike Mendis, SR Page · 2009 · Expert Opinion on Pharmacotherapy
14. Does treatment of hypertension decrease the incidence of atrial fibrillation and cardioembolic stroke?
    Boris Solun, Dana Marcoviciu, Dror Dicker · 2008 · European Journal of Internal Medicine
15. Blood pressure targets, medication considerations and special concerns in elderly hypertension: Focus on atherosclerotic cardiovascular diseases, atrial fibrillation, heart failure, and aortic stenosis
    Ru-Yin Hsu, Hao-Yun Lo, Chien-Hao Chen, Yee-Jen Wu, Ding‐Cheng Chan, Chih‐Cheng Wu, Tzung‐Dau Wang, Hsien‐Li Kao, Wen‐Jung Sun, Yen‐Hung Lin et al. · 2025 · Journal of the Formosan Medical Association
16. Combined effects of up- and downstream therapies on atrial fibrillation in a canine rapid stimulation model
    Hidehira Fukaya, Shinichi Niwano, Hiroe Niwano, Yoshihiko Masaki, Michiro Kiryu, Shoji Hirasawa, Daisuke Satoh, Masahiko Moriguchi, Tohru Izumi · 2010 · International Journal of Cardiology
17. Wytyczne ESH/ESC dotyczące postępowania w nadciśnieniu tętniczym w 2013 roku
    Kardiologia Polska Suplement · 2013 · Kardiologia Polska
18. Atrial Fibrillation in Heart Failure—Diagnostic, Therapeutic, and Prognostic Relevance
    Clara Stegmann, Gerhard Hindricks · 2019 · Current Heart Failure Reports
19. Atrial fibrillation in patients with systolic heart failure: pathophysiology mechanisms and management.
    Ioanna C. Koniari, Eleni Artopoulou, Dimitrios Velissaris, Nicholas George Kounis, Grigorios Tsigkas · 2021 · PubMed Central
20. Modifiable Risk Factors and Atrial Fibrillation: the Quest for a Personalized Approach
    Lavinia-Lucia Matei, Cǎlin Silişte, Dragoş Vinereanu · 2021 · MAEDICA – a Journal of Clinical Medicine
21. Candesartan Cilexetil Attenuates Arrhythmogenicity Following Pressure Overload in Rats via the Modulation of Cardiac Electrical and Structural Remodeling and Calcium Handling Dysfunction
    Gwo‐Jyh Chang, Yung‐Hsin Yeh, Wei-Jan Chen, Yu‐Shien Ko, Ying‐Ju Lai, Yun‐Shien Lee · 2022 · Journal of the American Heart Association
22. Confirm Rx insertable cardiac monitor for primary atrial fibrillation detection in high‐risk heart failure patients ( Confirm‐AF trial)
    Mehmet K. Aktaş, Wojciech Zaręba, Javed Butler, Arwa Younis, Scott A McNitt, Mary W. Brown, Nikhila Rao, Nilesh Rao, Jonathan S. Steinberg, Leway Chen et al. · 2022 · Annals of Noninvasive Electrocardiology
23. Pharmacological management of atrial fibrillation in patients with heart failure with reduced ejection fraction: review of current knowledge and future directions
    Alex F. Grubb, Robert John Mentz · 2020 · Expert Review of Cardiovascular Therapy
24. Reviewing the future of renin-angiotensin system blockade: The role of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in the prevention of atrial fibrillation
    Anique Ducharme, Ernesto L. Schiffrin · 2010 · Canadian Journal of Cardiology
25. Biomarkers for prognosis in atrial fibrillation: unfulfilled hopes
    Beata Wożakowska−Kapłon, Radosław Bartkowiak · 2015 · Polskie Archiwum Medycyny Wewnętrznej
26. Current Management Strategies in Patients with Heart Failure and Atrial Fibrillation: A Review of the Literature
    Alex Michael Parker, Juan Ramon Vilaro, Mustafa Mohammed Ahmed, Juan M. Aranda · 2020 · Cardiovascular Innovations and Applications
27. Atrial arrhythmias and heart failure: A “modern view” of an old paradox
    Beniamino Pagliaro, Gianluca Mincione, Antonio Taormina, Carlo Ceriotti, Luca Poggio, Francesco Cannata, Guido Del Monaco, Mauro Gitto, Vincenzo Battaglia, Gabriele Pinna et al. · 2023 · Pacing and Clinical Electrophysiology
28. Beneficial effects of losartan for prevention of paroxysmal atrial fibrillation in patients with sick sinus syndrome: analysis with memory function of pacemaker
    Eiichi Takii, Tomohito Inage, Teruhisa Yoshida, Masatsugu Ohe, Takeki Gondo, Go Haraguchi, Shogo Ito, Jun Kumanomido, Tsutomu Imaizumi, Yoshihiro Fukuomoto · 2015 · Heart and Vessels
29. Changes in blood pressure classification, blood pressure goals and pharmacological treatment of essential hypertension in medical guidelines from 2003 to 2013
    Tam Tran, Nhat Minh Giang · 2014 · IJC Metabolic & Endocrine
30. Usefulness of pulsed-wave tissue Doppler imaging at the mitral annulus for prediction of new-onset atrial fibrillation in dogs
    J. Neves, Brigite Pedro, Robert Christley, Joanna Dukes‐McEwan · 2018 · Journal of Veterinary Cardiology
31. Atrial Functional Mitral and Tricuspid Regurgitation
    Sébastien Deferm, Jeroen Dauw, Pieter M. Vandervoort, Philippe B. Bertrand · 2020 · Current Treatment Options in Cardiovascular Medicine
32. The CHARM program: the effects of candesartan for the management of patients with chronic heart failure
    Robert Samuel McKelvie · 2008 · Expert Review of Cardiovascular Therapy
33. The Importance of Integrated Risk Management When Treating Patients with Hypertension: Benefits of Angiotensin II Receptor Antagonist Therapy
    Luis Miguel Ruilope, J. Segura · 2008 · Clinical and Experimental Hypertension
34. Pathophysiology of atrial fibrillation: Insights into the renin–angiotensin system
    Jean‐Yves Le Heuzey, Éloi Marijon, Karim Chachoua, Xavier Waintraub, Antoine Lepillier, Akli Otmani, Thomas Lavergne, Maurice Pornin · 2008 · Archives of cardiovascular diseases
35. Prevención de la fibrilación auricular en el paciente hipertenso
    Vivencio Barrios Alonso, Mariano de la Figuera von Wichmann, Antonio Coca Payeras · 2007 · Medicina Clínica
36. Association between the use of non-antiarrhythmic drugs and postoperative atrial fibrillation
    Mehmet Özaydın, Yasin Türker, Oktay Peker, Doğan Erdoğan, Ercan Varol, Abdullah Doğan, Erdoğan İbrişim · 2009 · International Journal of Cardiology
37. Current Role of Medical Therapy for Prevention or Termination of Atrial Fibrillation
    Adrian M Baranchuk, Carlos Arturo Morillo, Martin Thoenes, Rodolpho Ventura, Stuart J. Connolly · 2008 · Humana Press eBooks
38. Addressing Extracardiac Risk Factors to Improve Atrial Fibrillation Treatment Outcomes
    Jason G. Andrade, Laurent Macle · 2019 · Journal of Innovations in Cardiac Rhythm Management
39. Low plasma renin activity is associated with “Apparently” idiopathic atrial fibrillation
    Youmei Shen, Guodong Ma, Min Sun, Mingfang Li, Minglong Chen · 2023 · IJC Heart & Vasculature
40. Rapid Uptitration of Guideline-Directed Medical Therapies in Acute Heart Failure With and Without Atrial Fibrillation
    Dimitrios T. Farmakis, Beth A. Davison, Katerina Fountoulaki, Sotiria Liori, Ovidiu Chioncel, Marco Metra, Jelena Čelutkienė, Alain Cohen Solal, Albertino Antonio Moura Damasceno, Rafael Díaz et al. · 2024 · JACC Heart Failure
41. Candesartan cilexetil in the treatment of chronic heart failure
    Jean-Philippe Baguet · 2009 · Vascular Health and Risk Management
42. The clinical implication of new‐onset in‐hospital atrial fibrillation in patients with acute decompensated heart failure
    Masashi Kamioka, Akiomi Yoshihisa, Minoru Nodera, Tomofumi Misaka, Tetsuro Yokokawa, Takashi Kaneshiro, Kazuhiko Nakazato, Takafumi Ishida, Yasuchika Takeishi · 2020 · Journal of Arrhythmia
43. Rhythm Control of Atrial Fibrillation in Heart Failure with Reduced Ejection Fraction
    Gregory M. Burkman, Gerald V. Naccarelli · 2020 · Current Cardiology Reports
44. Atrial Fibrillation in Patients with Ischemic and Non-Ischemic Left Ventricular Dysfunction.
    Robin Ducas, Vignendra Ariyarajah · 2013 · Europe PMC (PubMed Central)
45. Blood Pressure Control versus Atrial Fibrillation Management in Stroke Prevention
    Carmine Savoia, Lidia Sada, Massimo Volpe · 2015 · Current Hypertension Reports
46. The effect of angiotensin receptor blockers for preventing atrial fibrillation
    Kristian Wachtell, Richard B. Devereux, Paulette A. Lyle · 2007 · Current Hypertension Reports
47. Renin-Angiotensin System and AtrialFibrillation:Understanding the Connection.
    Marcello Disertori, Silvia Quintarelli · 2011 · Europe PMC (PubMed Central)
48. Treatment Considerations for a Dual Epidemic of Atrial Fibrillation and Heart Failure.
    Parikshit S. Sharma, David J. Callans · 2013 · Europe PMC (PubMed Central)
49. Mineralocorticoid Receptor Antagonism for the Treatment of AF and HFpEF
    Adam D. DeVore, Jonathan Paul Piccini · 2018 · JACC Heart Failure
50. Atrial Fibrillation Management with Guideline-Directed Medical Therapy and Comorbidity Treatment in Heart Failure Patients
    Alvise Del Monte, Andrea Sarkozy, Frederik Hendrik Verbrugge · 2024 · Cardiac Electrophysiology Clinics
51. Candesartan for the management of heart failure: more than an alternative
    Robert Samuel McKelvie · 2006 · Expert Opinion on Pharmacotherapy
52. INACTIVATION OF RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM. WHICH CLASS OF ANTIHYPERTENSIVE MEDICINE PRODUCTS TO PREFER?
    Сергей Валентинович Столов · 2020 · Eurasian heart journal
53. Effects of angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker on one-year outcomes of patients with atrial fibrillation: insights from a multicenter registry study in China.
    Si‐qi Lyu, Yanmin Yang, Jun Zhu, Juan Wang, Shuang Wu, Jiameng Ren, Han Zhang, Xing‐hui Shao · 2020 · Europe PMC (PubMed Central)
54. Non-antiarrhythmic medications for atrial fibrillation: From bench to clinical practice
    Maya E. Guglin, Marcos Garcia, Michael J. Yarnoz, Anne B. Curtis · 2008 · Journal of Interventional Cardiac Electrophysiology
55. Management of atrial fibrillation in patients with heart failure: from drug therapy to ablation
    Wanwarang Wongcharoen, Shih‐Ann Chen · 2009 · Expert Review of Cardiovascular Therapy
56. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program
    Albert L. Waldo · 2007 · Yearbook of Cardiology
57. Atrial Fibrillation Development in the Heart Failure Population from Nationwide British Linked Electronic Health Records
    Hiroyuki Yoshimura, Nikhil Paliwal, Arturo González-Izquierdo, Chris Finan, Amand Floriaan Schmidt, Gregory Y.H. Lip, Rui Andre Providencia · 2025 · ESC Heart Failure
58. Randomized placebo controlled blinded study to assess valsartan efficacy in preventing left ventricle remodeling in patients with dual chamber pacemaker — Rationale and design of the trial
    Andrzej Robert Tomasik, Wojciech Jacheć, Celina Wojciechowska, Damian Kawecki, Beata Białkowska, Ewa Barbara Romuk, Artur Gabrysiak, Ewa Birkner, Zbigniew F. Kalarus, Ewa Nowalany-Kozielska · 2015 · Contemporary Clinical Trials
59. Arrythmia-Mediated Valvular Heart Disease
    Sébastien Deferm, Philippe B. Bertrand, Sebastiaan Dhont, Ralph Stephan von Bardeleben, Pieter M. Vandervoort · 2023 · Heart Failure Clinics
60. Angiotensin II receptor blockers in the prevention of atrial fibrillation
    Silvia Barra, Nunzia Silvestri, Giancarlo Vitagliano, Alfredo Madrid, Giovanni Gaeta · 2009 · Expert Opinion on Pharmacotherapy
61. Experimental Evaluation of Myocardial Fibrosis in a Rapid Atrial Pacing Model in New Zealand Rabbits using Quantitative Analysis of Ultrasonic Backscatter
    Yitong Ma · 2014 · Medical Science Monitor
62. Atrial Fibrillation and Heart Failure: How Should We Manage Our Patients?
    Farhan Shahid, Gregory Y.H. Lip · 2016 · Arrhythmia & Electrophysiology Review
63. Angiotensin II receptor blockers in the prevention of complications from atrial fibrillation
    Stephanie Eide · 2009 · Vascular Health and Risk Management
64. Prevention of atrial fibrillation in hypertension
    Tonje Amb Aksnes, Arnljot Flaa, Arne H. Strand, Sverre Erik Kjeldsen · 2008 · Current Hypertension Reports
65. 2024 Thai guidelines on the treatment of hypertension
    Sirisawat Kunanon, Praew Kotruchin, Pairoj Chattranukulchai, Chavalit Chotruangnapa, Weranuj Roubsanthisuk, Prin Vathesatogkit, Tada Kunavisarut, Songkwan Silaruks, Sirakarn Tejavanija, Tuangsit Wataganara et al. · 2025 · Asian Biomedicine
66. Adverse Outcomes from Atrial Fibrillation;Mechanisms, Risks, and Insights Learned from Therapeutic Options.
    David L Johnson, John D Day, Srijoy Mahapatra, Thomas Jared Bunch · 2012 · Europe PMC (PubMed Central)
67. Association between types of antihypertensive medication and the risk of atrial fibrillation: a nationwide population study
    Jung‐Min Choi, So‐Ryoung Lee, Eue‐Keun Choi, Kyung‐Yeon Lee, Hyo‐Jeong Ahn, Soonil Kwon, Bongseong Kim, Kyungdo Han, Seil Oh, Gregory Y.H. Lip · 2024 · Frontiers in Cardiovascular Medicine
68. Functional Mitral Regurgitation and the Role of Transcatheter Repair
    Richa Gupta, Holly M. Gonzales, Stacy Tsai, Angela M. Lowenstern, JoAnn Lindenfeld · 2024 · Structural Heart
69. Novel Therapeutic Targets in the Management of Atrial Fibrillation
    Abhishek Maan, MOUSSA C. MANSOUR, David D. McManus, Vickas V. Patel, Alan Cheng, Jeremy Neil Ruskin, Edwin Kevin Heist · 2014 · American Journal of Cardiovascular Drugs
70. Angiotensin II blockade, YKL-40 and maintenance of sinus rhythm after electrical cardioversion for atrial fibrillation
    Arnljot Tveit, Ingebjørg Seljeflot, Pål Smith, Harald Arnesen, Jesper Hastrup Svendsen · 2013 · Immunobiology
71. Upstream approach for atrial fibrillation.
    Koichiro Kumagai · 2010 · Folia Pharmacologica Japonica
72. Renin-Angiotensin System Blockade Is Associated with the Long-Term Protection Against Cardiac Remodeling after Cardioversion in Hypertensive Patients with Atrial Fibrillation
    Yasuyuki Egami, Masami Nishino, Masayuki Taniike, Nobuhiko Makino, Hiroyasu Kato, Ryu Shutta, Hitoshi Yamaguchi, Jun Tanouchi, Yoshio Yamada · 2010 · The Tohoku Journal of Experimental Medicine
73. Cardio classics revisited – focus on the role of candesartan
    Maria Leonarda De Rosa · 2010 · Vascular Health and Risk Management
74. Use of Predictive Markers to Improve Cardiovascular Protection
    Giuliano Tocci, Francesco Paneni, Beatrice Ponziani, Massimo Volpe · 2007 · Future Cardiology
75. Traiter la fibrillation atriale dans l’insuffisance cardiaque
    Jean‐Yves Le Heuzey, Éloi Marijon, Akli Otmani, Antoine Lepillier, Xavier Waintraub, Thomas Lavergne, Maurice Pornin · 2009 · Therapies
76. Upstream-Therapie bei Vorhofflimmern
    Andreas Goette, Matthias Hammwöhner, Alicja Bukowska · 2014 · Herzschrittmachertherapie + Elektrophysiologie
77. 2018 Korean Heart Rhythm Society Guidelines for Detection and Management of Risk Factors and Concomitant Cardiovascular Diseases in Korean Patients with Atrial Fibrillation
    So‐Ryoung Lee, Young Soo Lee, Woo‐Hyun Lim, Tae‐Hoon Kim, Myung‐Jin Cha, Ji Hyun Lee, Yong‐Soo Baek, Hong Euy Lim, Boyoung Joung, June Soo Kim et al. · 2018 · Korean Journal of Medicine
78. Risk Alteration for Atrial Fibrillation with DifferentAntihypertensive Drugs.
    Vivencio Barrios, Carlos Escobar · 2011 · Europe PMC (PubMed Central)
79. Clinical features of dialysis patients with atrial fibrillation
    Hideki Fujii, Kunihiko Yoshiya, Jong II Kim, Takaya Abe, Michio Umezu, Masafumi Fukagawa · 2007 · Nihon Toseki Igakkai Zasshi
80. Primary Prevention of Atrial Fibrillation - The Path Untread.
    Joel A. Lardizabal, PRAKASH C. DEEDWANIA · 2013 · Europe PMC (PubMed Central)
81. Atrial Fibrillation: Upstream Therapies
    Antonios Kourliouros, Irina Savelieva, Marjan Jahangiri, A. John Camm · 2009 · Wiley eBooks
82. Candesartan: from left ventricular hypertrophy to heart failure, a global approach
    Vivencio Barrios, Carlos Escobar, Alberto Calderón · 2007 · Expert Review of Cardiovascular Therapy
83. Should aldosterone blockade be used beyond current indications in heart failure?
    Marcelle D. Smit, Isabelle C. Van Gelder, Michael Böhm, Hans‐Ruprecht Neuberger, Dirk Jan van Veldhuisen · 2009 · Current Heart Failure Reports
84. Cardiología (ESC) Desarrolladas con la contribución especial de European Heart Rhythm Association (EHRA) Aprobado por European Association for Cardio-Thoracic Surgery (EACTS)
    A. John Camm, Paulus F. Kirchhof, Sabine Ernst, Isabelle C. Van Gelder, Gerhard Hindricks, Hein Heidbüchel, Paolo Colonna, Andreas Goette, Stefan H. Hohloser, Philippe H. Kolh et al. · 2010
85. Management of atrial fibrillation in patients with heart failure with preserved ejection fraction
    Paula K. Rambarat, Adam D DeVore, Daniel B. Mark, Tristam D. Bahnson, Jonathan Paul Piccini · 2025 · Heart Failure Reviews
86. Left Atrial Dysfunction in Patients with Atrial Fibrillation and Heart Failure
    Cory Ross Trankle, Ajay Pillai, Hussein Krayem, Keyur B. Shah, Kenneth A. Ellenbogen, W. Gregory Hundley · 2025 · Current Cardiology Reports
87. The role of the renin–angiotensin system blocking in the management of atrial fibrillation
    Brett Cliff, Naveed Younis, Salam Hama, Handrean Soran · 2012 · Journal of Drug Assessment
88. Atrial Fibrillation Revisited —With a Special Reference to Primary Prevention—
    Y. Aizawa, H. Furushima, Hiroshi Watanabe · 2007 · Journal of Arrhythmia
89. Highlights from the fifth international symposium of thrombosis and anticoagulation (ISTA V), october 18–19, 2012, Belo Horizonte, Minas Gerais, Brazil
    Renato D. Lópes, Richard Clinton Becker, Laura Kristin Newby, Eric David Peterson, Elaine M. Hylek, Robert Patrick Giugliano, Christopher Bull Granger, Kenneth W. Mahaffey, Antônio Carlos Carvalho, Otavio B Berwanger et al. · 2013 · Journal of Thrombosis and Thrombolysis
90. Selecting Optimum Antihypertensive Therapy
    Vasilios Papademetriou, Michael N. Doumas · 2016 · Springer eBooks
91. Chronic Atrial Fibrillation
    Joel A. Lardizabal, Sanjiv Sharma · 2013 · Journal of Hypertension and Cardiology
92. Catheter ablation: is that a new era in treatment of atrial fibrillation among patients with chronic heart failure?
    Сапельников Олег Валерьевич, Ардус Дарин Фаресовна, O. A. Nikolaeva, D. I. Cherkashin, Igor Yu. Grishin, A. A. Kulikov, И. В. Жиров, Tatiana M. Uskach, Sergey N. Tereshchenko, Renat S. Akchurin · 2018 · Russian Cardiology Bulletin
93. Type 1 angiotensin II receptor antagonists in cardiovascular diseases: Valsartan
    Yu. V. Sviryaev, Н. Э. Звартау · 2011 · Arterial’naya Gipertenziya (Arterial Hypertension)
94. Correlation between Atrial Fibrillation and Heart Failure with Preserved Ejection Fraction: A Review
    Prasad RM, Sandeep Banga, Salazar AM, Majid Yavari, P Pandrangi, Zulfiqar Qutrio Baloch, Ip J · 2022 · Austin Journal of Cerebrovascular Disease & Stroke
95. Gambaran Pemberian Ace Inhibitor atau Angiotensin Receptor Blocker pada Pasien Gagal Jantung di RSUD Ulin Banjarmasin
    Nurazizah Yunus, Dwi Laksono Adiputro, Agung Biworo, Mohammad Rudiansyah, Oski Illiandri · 2022 · Homeostasis
96. Up-Titration of Medication in Patients with New-Onset Heart Failure with and Without Atrial Fibrillation
    Arietje J.L. Zandijk, Bernadet T. Santema, Friso D.J. Inkelaar, Martje H.L. van der Wal, Janke Warink‐Riemersma, Michiel Rienstra, Adriaan A. Voors · 2025 · ESC Heart Failure
97. Clinical Prediction Rule for the Development of New Onset Postoperative Atrial Fibrillation After Cardiac Surgery
    DiemThu Thi Tran · 2013
98. Long‐term observation of fibrillation cycle length in patients under angiotensin II receptor blocker therapy for chronic atrial fibrillation
    Jun Kishihara, Shinichi Niwano, Hiroe Niwano, Yuya Aoyama, Shoko Ishikawa, Jun Oikawa, Akira Sato, Masami Murakami, Michiro Kiryu, Tohru Izumi · 2012 · Journal of Arrhythmia
99. Role Of Glycemic Control In Development Of Atrial Fibrillation In Patients With Type 2 Diabetes Mellitus
    Mukul Singhal, Carrie McAdam-Marx, Josiane Lafleur, DM Witt, RE Nelson, J.E. Biskupiak · 2016 · Value in Health
100. CANDESARTAN IN CARDIOLOGY PRACTICE
     Джаиани Нино Амирановна · 2017 · Meditsinskiy sovet = Medical Council